Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for ABT and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ABT and 80,000+ other tickers.
See exactly how ABT's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ABT and 80,000+ other tickers.
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm…
Drug pricing is back on the front page, and healthcare investors have barely flinched. The White House's latest round of most-favored-nation pricing agreements brought nine more manufacturers into the fold, pushing the total to 26 companies covering 89% of the branded drug market.
Owning these dividend stocks could be a simple way to make money over the long term.
Benjamin Edwards Inc. trimmed its position in Abbott Laboratories (NYSE: ABT) by 35.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 230,949 shares of the healthcare product maker's stock after selling 127,686 shares during the quarter. Benjamin
A. D. Beadell Investment Counsel Inc. increased its position in shares of Abbott Laboratories (NYSE: ABT) by 28.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 34,819 shares of the healthcare product maker's stock after buying an additional
Advocacy Wealth Management LLC decreased its stake in Abbott Laboratories (NYSE: ABT) by 6.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 115,947 shares of the healthcare product maker's stock after selling 8,064 shares during the quarter. Advocacy